ReachRxResearch
Home
Research
Sign Up
  1. Home
  2. Research Hub
  3. Sexual orientation and gender identity b…

Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States

Cancer·July 6Open Access
OncologySafety signalBreast CancerCervical CancerColorectal CancerCross-Sectional StudyMixed

Summary

View source

What was studied

This cross-sectional study used 2018–2022 BRFSS data (n=663,924 screening-eligible adults) to evaluate whether sexual orientation minority (SOM) or gender identity minority (GIM) status was associated with adherence to USPSTF-recommended colorectal (CRC), cervical, and breast cancer screening, compared with heterosexual and cisgender respondents respectively.

Key findings

After adjustment, SOM women had lower cervical (aPR 0.92; 95% CI 0.87–0.97) and breast cancer screening adherence (aPR 0.84; 95% CI 0.77–0.92) vs. heterosexual women; GIM women had markedly lower cervical (aPR 0.58; 95% CI 0.37–0.90) and breast screening adherence (aPR 0.24; 95% CI 0.08–0.74) vs. cisgender women. SOM men had slightly higher CRC screening adherence (aPR 1.10; 95% CI 1.00–1.21). No CRC screening disparity was seen for GIM. Female-to-male transgender individuals had 50% lower cervical screening adherence vs. cisgender women (aPR 0.50; 95% CI 0.30–0.84). A Blinder–Oaxaca decomposition showed 64% of the cervical screening gap in SOM women was explained by sociodemographic factors (insurance status contributing most), with 36% unexplained.

Study limitations

- SOGI module was optional and administered in select states only, so the analytic sample is not nationally representative and missingness is unlikely random. - Cross-sectional self-report design introduces recall bias and SOGI misclassification; the survey lacks a two-step sex/gender measure, likely underestimating GIM disparities. - Very small GIM subgroup sizes (e.g., n=130 for cervical screening) yield wide confidence intervals and limit precision of transgender subgroup analyses.

Clinical implications

Clinicians should proactively offer cervical and breast cancer screening to sexual and gender minority patients, using inclusive, non-heteronormative language and anatomy-based (rather than administrative gender–based) eligibility criteria. Self-collected HPV testing is a practical option to improve cervical screening uptake among female-to-male transgender individuals who may avoid traditional women's health settings.

Related Questions

Explore related topics

What are the barriers to cervical cancer screening in transgender men and how can clinicians address them?How does sexual minority status affect mammography screening rates compared to heterosexual women?What interventions improve cancer screening uptake among LGBTQ+ patients in primary care?

Publication Details

Year
2026
Journal
Cancer
Sample Size
n=663,924
Source
View article
Keep scrolling
More content below.
Up Next